Screener
Medtronic MDT Diabetes — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Medtronic’s 10-Q, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:18 PM EST
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-011107
| (in millions) | Cardiovascular | Neuroscience | Medical Surgical | Diabetes | Total |
|---|---|---|---|---|---|
| Total consolidated net sales | $9,017 | ||||
| Less: | |||||
| Cost of products sold, excluding amortization of intangible assets | 1,159 | 815 | 867 | 332 | 3,173 |
| Research and development expense | 284 | 153 | 174 | 109 | 720 |
| Selling, general, and administrative expense | 1,129 | 841 | 628 | 300 | 2,897 |
| Other segment items(2) | (14) | 12 | 6 | (2) | 3 |
| Reportable segment operating profit | $899 | $737 | $499 | $57 | $2,192 |
| Reconciliation of segment profit / (loss) |
Item 1. Financial Statements
FAQ
- What is Medtronic's diabetes — research and development expense?
- Medtronic (MDT) reported diabetes — research and development expense of $109M in Q4 2025.
- How has Medtronic's diabetes — research and development expense changed year-over-year?
- Medtronic's diabetes — research and development expense increased by 0.9% year-over-year, from $108M to $109M.
- What is the long-term trend for Medtronic's diabetes — research and development expense?
- Over 2 years (2023 to 2025), Medtronic's diabetes — research and development expense has grown at a 1.1% compound annual growth rate (CAGR), from $392M to $401M.
- What does diabetes — research and development expense mean?
- This captures the investment in innovation, clinical trials, and engineering for new diabetes management technologies and software. It reflects the company's commitment to maintaining a competitive pipeline of insulin delivery and glucose sensing devices. High spending is essential for long-term growth in the highly competitive medical technology market.
Ask your AI about Medtronic's diabetes — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude